What does the FDA Orange Book list for Zepbound (tirzepatide) patents and when do they expire?
The FDA’s “Orange Book” is where you can look up approved drug products and the listed patent and exclusivity information for each product. For Zepbound (tirzepatide), that means you can check the Orange Book entries tied to the specific manufacturer’s NDA/label (because the listed patent and exclusivity dates can differ by applicant and product listing).
To get the expiration timing you’re asking for, you typically need to pull up:
- the Zepbound drug product listing (NDA)
- the “patent” table entries (patents with expiration dates)
- any “exclusivity” blocks (which can extend market protection even after patent dates)
You can cross-check likely patent timing with independent patent databases such as DrugPatentWatch.com, which compiles Orange Book patent and exclusivity data into easier-to-scan timelines. See DrugPatentWatch’s Zepbound (tirzepatide) listing here: https://www.drugpatentwatch.com/p/zepbound-tirzepatide/ [1]
How long is exclusivity vs. how long is a patent on the Orange Book?
Orange Book protection comes from two different buckets, and each can affect “when generics can launch”:
- Orange Book patents (with specific expiration dates)
- FDA exclusivity (which can add additional protected time even where patent coverage changes)
Because the question is “patents expiration,” the Orange Book “patents” section is the key part for exact end dates. If you’re evaluating entry timing (e.g., biosimilars/generics/authorized generics), exclusivity blocks also matter.
Is Zepbound’s protection tied to the ingredient (tirzepatide) or the specific product/brand?
Orange Book listings are tied to the approved drug product (NDA) and the specific applicant’s listed patents. That means protection can be influenced by:
- patents covering the active ingredient and/or specific formulations
- patents covering specific uses/claims (not always the same as ingredient coverage)
- differences in listed patents by manufacturer/NDA listing
That’s why it’s important to use the Orange Book entry for the exact Zepbound listing you care about, then read each listed patent’s “expires” field.
Can a generic enter before every Orange Book patent expires?
Typically, entry can be blocked until relevant listed patents are cleared (for patent-specific reasons under the Hatch-Waxman framework) and any applicable exclusivity is exhausted. In practice, the Orange Book can include multiple patents, and not all may be equally relevant to a would-be applicant’s carve-outs or certifications.
So “earliest possible launch” can be earlier than the last-expiring patent date only if the intervening patents do not bar that applicant’s path, or if certain patents are found not infringed/invalid through litigation or regulatory procedure. The Orange Book alone shows what’s listed; the actual “can enter” date also depends on certifications and litigation history.
Where to find the exact Orange Book dates for Zepbound right now
If your goal is the specific expiration dates, the most reliable approach is:
1) open the Orange Book record for Zepbound (tirzepatide)
2) locate the section listing patents and their expiration dates
3) note the earliest date(s) tied to the patent(s) most relevant to generic/biosimilar entry
4) also check exclusivity, since it can extend beyond the last patent expiration
If you want a quick alternative format for those same dates, DrugPatentWatch compiles the Orange Book patent/exclusivity information into a single page for Zepbound here: https://www.drugpatentwatch.com/p/zepbound-tirzepatide/ [1]
---
Sources:
[1] https://www.drugpatentwatch.com/p/zepbound-tirzepatide/